Table 1.
Patient characteristics and clinical, pathological, and treatment-related parameters.
| Variables | Test Cohort (n = 1931) | Validation Cohort (n = 1085) | ||||
|---|---|---|---|---|---|---|
| N (%) | Missing (%) | N (%) | Missing (%) | p-Value * | ||
| Age (continuous; years; median + IQR) | 59 (44.7–70) | 45 (2.3) | 61 (47–74) | 0 (0.0) | <0.0001 | |
| Gender | Male | 1038 (53.8) | 0 (0.0) | 615 (56.7) | 0 (0.0) | 0.121 |
| Female | 893 (46.2) | 470 (43.3) | ||||
| Tumor Location | Upper Extremity | 520 (26.9) | 1 (0.05) | 312 (28.8) | 0 (0.0) | 0.285 |
| Lower Extremity | 1410 (73.1) | 773 (71.2) | ||||
| Depth | Epifascial | 518 (26.9) | 2 (0.1) | 291 (26.8) | 0 (0.0) | 0.984 |
| Subfascial | 1411 (73.1) | 794 (73.2) | ||||
| Tumor Size (continuous; cm; median + IQR) | 7 (4–11) | 30 (1.6) | 7.5 (5–12) | 5 (0.5) | 0.026 | |
| Histology | Myxoid liposarcoma | 222 (11.6) | 16 (0.8) | 111 (10.2) | 0 (0.0) | <0.0001 |
| MPNST | 83 (4.3) | 43 (4.0) | ||||
| Myxofibrosarcoma | 451(23.6) | 104 (9.6) | ||||
| Synovial Sarcoma | 174 (9.1) | 79 (7.3) | ||||
| UPS | 325 (17.0) | 375 (34.6) | ||||
| Angiosarcoma/Vascular Sarcoma | 22 (1.1) | 20 (1.8) | ||||
| Dedifferentiated/Pleomorphic Liposarcoma | 141 (7.4) | 85 (7.8) | ||||
| Leiomyosarcoma | 221 (11.5) | 118 (10.9) | ||||
| Others | 276 (14.4) | 150 (13.8) | ||||
| Grading | G2 | 719 (37.8) | 30 (1.6) | 382 (35.8) | 19 (1.8) | 0.282 |
| G3 | 1182 (62.2) | 684 (64.2) | ||||
| Margins | R0 | 1494 (77.4) | 0 (0.0) | 768 (70.8) | 0 (0.0) | <0.0001 |
| R1/2 | 437 (22.6) | 317 (29.2) | ||||
| CTX | No | 1408 (73.0) | 1 (0. 05) | 1039 (95.8) | 0 (0.0) | <0.0001 |
| Neoadjuvant | 262 (13.6) | 40 (3.7) | ||||
| Adjuvant | 209 (10.8) | 6 (0.6) | ||||
| Neoadjuvant + Adjuvant | 51 (2.6) | 0 (0.0) | ||||
| RTX | No | 619 (32.9) | 50 (2.6) | 335 (30.9) | 0 (0.0) | <0.0001 |
| Neoadjuvant | 303 (16.1) | 460 (42.4) | ||||
| Adjuvant | 956 (50.8) | 275 (25.4) | ||||
| Neoadjuvant + Adjuvant | 3 (0.2) | 15 (1.4) | ||||
| Follow-up (continuous; months; median + IQR) | 50 (23.3–95) | 11 (0.6) | 56 (21–91) | 0 (0.0) | 0.254 | |
* p-values calculated with Wilcoxon rank sum test for continuous variables, with chi2-test for binary and categorical variables. p-values in bold are considered statistically significant. Abbreviations: CTX = chemotherapy. IQR = interquartile range. MPNST = Malignant Peripheral Nerve Sheat Tumor. RTX = radiotherapy. UPS = Undifferentiated pleiomorphic sarcoma.